HELP Apheresis in the treatment of sepsis

Artificial Organs

Volumn 22, Issue 1, 1998, Pages 43-46

  Samtleben, W ^a   Bengsch, S ^a   Boos, K S ^a   Seidel, D ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Apheresis; Endotoxin removal; Sepsis

Indexed keywords

ADSORPTION; CELLULOSE; CHOLESTEROL; LIPOPROTEINS; PH;

ADSORBERS; APHERESIS; C-REACTIVE PROTEINS; ENDOTOXIN REMOVAL; HYPERCHOLESTEROLEMIA; IN-VITRO; LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEINS; SEPSIS; TNF Α;

SULFUR COMPOUNDS;

2 DIETHYLAMINOETHANOL; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CELLULOSE; CHOLESTEROL; DEXTRAN SULFATE; ENDOTOXIN; FIBRINOGEN; HEPARIN; TUMOR NECROSIS FACTOR ALPHA;

ADSORPTION; APHERESIS; CASE REPORT; CONFERENCE PAPER; ENDOTOXEMIA; EXTRACORPOREAL CIRCULATION; GRAM NEGATIVE SEPSIS; HUMAN; PRIORITY JOURNAL;

NEGIBACTERIA;

EID: 0031915597     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.1998.06011.x     Document Type: Conference Paper

References (21)

1. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. NIH Conference. Ann Int Mes 1994;120:771-83.
2. Pilz G, Kreuzer E, Kääb S, Appel R, Werdan K. Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified high-risk patients. Chest 1994;105:76-82.
3. Cometta A, Baumgartner JD, Glauser MP. Polyclonal intravenous immune globuline for prevention and treatment of infections in critically ill patients. Clin Exp Immunol 1994;97: 69-72.
4. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Braude AI. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982;307:1225-30.
5. Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, Quenzer RW, Iberti TJ, Macintyre N, Schein RMH, the E5 Sepsis Study Group. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, mullicenter, randomized, controlled trial. Crit Care Med 1995;23:994-1005.
6. Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russel JA, the XQMA Sepsis Study Group. A controlled trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991; 266:1097-102.
7. Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel C, Fink MP, Dellinger RP, Teng NNH, Allen E, Berger HJ, Knatterud GL, LoBuglio AF, Smith CR, the HA-1A Sepsis Study Group. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1991;324:429-36.
8. Abraham E, Wundernik R, Silverman H, Perl TM, Nasaway S, Levy H, Bone R, Wenzel RP, Balk R, Allre R, Pennington JE, Wherry RP, the TNF-α Mab Sepsis Study Group. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. JAMA 1995;273: 934-41.
9. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RMH, Benjamin E, for the Soluble TNF Receptor Sepsis Study Group. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996;334:1697-702.
10. Fisher JH, Dhainaut JFA, Opal SM, Pribble JP, Balk RA, Slotsman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines D, Shelly MP, Thompson BW, LaBrecque JF, Catalano MA, Knaus WA, Sadoff JC, the Phase II rhIL-1a Sepsis Syndrome Study Group. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994;271:1836-42.
11. Hoffmann JH, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D. Hemofiltration in human sepsis: Evidence for elimination of immunomodulatory substances. Kidney Int 1995;48:1563-70.
12. Bellomo R, Tipping P, Boyce N. Interleukin-6 and interleukin-8 extraction during continuous venovenous hemodiafiltration in septic acute renal failure. Renal Failure 1995;17: 457-66.
13. Werdan K, Bauriedel G, Samtleben W, Banthien FCA, Haberl R, Hacker H, Roth P, Schultheiss HP, Gurland HJ, Authenrieth G. Plasma exchange in septic shock (in German). In: Deutsch G, Druml W, Kleinberger G, Ritz R, Schuster HP, eds. Aktuel Intensivmed 1986;3:429-37.
14. Reinke P. Plasmapheresis in the therapy of septic disease. Int J Artif Organs 1996;19:127-8.
15. Aoki H, Kodama M, Tani T, Hanasawa K. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994;167:412-7.
16. Kodama M, Tani T, Maekawa K, Hirasawa H, Otsuka T, Takahashi Y, Kaneko M. Endotoxin eliminating therapy in patients with severe sepsis-direct hemoperfusion using polymyxin B immobilized fiber column (in Japanese). Nippon Geka Gakkai Zasshi 1995;96:277-85.
17. Staubach K-H, Rosenfeldt J-A, Veit O, Bruch H-P. Extracorporeal adsorption of endotoxin. Ther Apheresis 1997;1:67-74.
18. Weber C, Rajnoch C, Loth F, Schima H, Falkenhagen D. The microspheres based detoxification system (MDS). Artif Organs 1994;17:595-602.
19. Samtleben W, Boos K-S, Fraunberger P, Briegel J, Haller M, Arendt R, Peter K, Seidel D. H.E.L.P. in gram-negative, refractory septic shock: First clinical experiences. Jpn J Apheresis 1997;16:91-6.
20. Schuff-Werner P, Seidel D. The H.E.L.P. system: Clinical experience of 10 years - a report. Jpn J Apheresis 1997;16:149-53.
21. Boos K-S, Bengsch S, Samtleben W, Seidel S. Elimination of LPS and/or TNFα from human plasma by adsorption-apheresis. In: Faist E, ed. The immune consequences of trauma, shock and sepsis. Mechanisms and therapeutic approaches. Bologna: Monduzzi Editore, 1997:799-803.